The European Partnership for Personalised Medicine, EP PerMed supported by the European Union under Horizon Europe, Grant Agreement N° 101137129, has launched its first research, innovation and technology call (RITC2026) for proposals on “Test and Demonstration of Multimodal Data Approaches for Personalised Medicine”, acronym “MultiPMData2026”. In total, 19 funding organisations participate in this call with an available budget of over 14.8 Mio. € (approx.).
This call aims to bring together enterprises with clinical actors, including healthcare providers, patients, and researchers, to test innovative solutions in controlled real-world settings to address clear needs in managing multimorbidity. EP PerMed will fund innovation projects in human health that focus on multimodal data usage for PM approaches aiming to provide more efficient and personalised management of patients with multimorbidity, having at least two chronic diseases that require management and adhere to the following definition:
In this call, a chronic disease is defined as a long-term health condition lasting 6 months or more, requiring management and significantly affecting health or activities of daily living. Chronic diseases include, but are not limited to, the following categories:
- Cardiovascular
- Metabolic
- Respiratory
- Neurological
- Immunological (including autoimmune)
- Gastrointestinal
- Uro-genital
- Cancer
- Mental health disorders
Projects should address one or more of the following aspects:
- Detection or characterisation of co-morbidities in chronically ill patients.
- Diagnosis, follow-up or monitoring of disease progression, including remissions and relapses.
- Promoting a shift from in-patient to out-patient care through remote monitoring or reporting using wearables or other technical solutions.
- Decision support for disease intervention strategies (e.g., medication type and dosage) .
- Tracking and managing multiple treatments (including drug combinations) to improve effectivenes or reduce adverse effects and potential harmful drug interactions.
- Adherence to long-term treatment regimens.
Solutions being tested should at least have reached the technology readiness level (TRL) 3 which in the current call is considered as successful proof-of-concept on relevant biological systems or clinical data.
While clinical studies (exploratory/proof-of-concept/early stage clinical studies or sub-studies) can be funded in this call, larger clinical trials are out of scope.
Joint research proposals may be submitted by applicants belonging to an entity according to the following categories (subject to regional/national funding regulations*):
A) Enterprise (for-profit) of all sizes, e.g. SME (small and medium-sized enterprises) and industry.
B) Clinical partner, public or private health sector represented by research teams or clinicians (e.g. medical doctors, nurses or pharmacists) working in hospitals/public health or other healthcare settings and health organisations.
C) Academia, research teams working in universities, other higher education institutions or public or private research institutes.
D) Private non-profit partners, e.g. foundations, associations or non-governmental organisations.
Consortia submitting applications to this call must include partners from categories A) and B), and are strongly encouraged to also include partners from categories C) and D).
* Requirements for entities from Navarra: Universities, Research Institutes, technological centers and companies that comply with points 2.2 and 2.5 a) and b) from the Resolution 466E/2024, of the 30 December. It can be found in the Official Navarrese Gazette #14, 13th February 2025 (https://bon.navarra.es/es/anuncio/-/texto/2025/30/7 ).
Eligibility criteria:
- Only transnational projects will be funded.
- Each consortium must include at least three partners from three different EU Member States or Associated Countries whose funding organisations participate in the call. Each of these partners must be eligible and request funding from the respective funding organisation. The legal entities must be independent of each other.
- At least one project partner must represent an enterprise (SME or industry), and at least one additional partner must be a clinical partner, adhering to categories A and B.
- The project coordinator (i.e. the principal investigator and the applicant’s organisation) must be eligible to be funded by their regional/national participating funding organisation. The project coordinator (i.e. the principal investigator and applicant’s organisation) cannot be changed during the application process.
Consortium composition:
- In both, the pre- and full proposal stage, no more than three partners from the same country, including partners on own funding, is allowed.
- In the pre-proposal phase, the maximum number of partners is seven.
- Widening concept: Consortia are allowed to include in the full proposal phase an additional project partner that is eligible to receive funding from a funding organisation that is underrepresented in the second stage of the call and that agrees to participate in the widening option (a list of underrepresented regions/countries will be provided to coordinators invited to submit full proposals).
- No more than two partners on own funds is allowed (partners on own funds must be additional to the minimum three partners eligible and requesting funding)
A two-stage submission and evaluation process will be used for joint applications, consisting of a preproposal stage and a full proposal stage.
In both stages, a single joint proposal (in English) must be prepared by the partners of the transnational consortium and submitted by one designated spokesperson, the coordinator, via the electronic submission system: https://ptoutline.eu/app/eppermedRITC2026.